SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study

Luna Colagrossi1, Maria Antonello2, Silvia Renica2, Marco Merli3, Elisa Matarazzo4, Giovanna Travi3, Marta Vecchi3, Jacopo Colombo5, Antonio Muscatello6,7, Giacomo Grasselli8, Silvia Nerini Molteni9, Vittorio Scaravilli8, Emanuele Cattaneo8, Diana Fantí9, Chiara Vismara9, Alessandra Bandera6,7, Andrea Gor6,7, Massimo Puoti3, Valeria Cento2, Claudia Alteri2* and Carlo Federico Perno1

Abstract

Background: Recent studies showed that plasma SARS-CoV-2 RNA seems to be associated with worse COVID-19 outcome. However, whether specific population can be at higher risk of viremia are to date unexplored.

Methods: This cross-sectional proof-of-concept study included 41 SARS-CoV-2-positive adult individuals (six affected by haematological malignancies) hospitalized at two major hospital in Milan, for those demographic, clinical and laboratory data were available. SARS-CoV-2 load was quantified by ddPCR in paired plasma and respiratory samples. To assess significant differences between patients with and patients without viremia, Fisher exact test and Wilcoxon test were used for categorical and continuous variables, respectively.

Results: Plasma SARS-CoV-2 RNA was found in 8 patients (19.5%), with a median (IQR) value of 694 (209–1023) copies/mL. Viremic patients were characterized by an higher mortality rate (50.0% vs 9.1%; p = 0.018) respect to patients without viremia. Viremic patients were more frequently affected by haematological malignancies (62.5% vs. 3.0%; p < 0.001), and had higher viral load in respiratory samples (9,404,000 [586,060–10,000,000] vs 1560 [312–25,160] copies/mL; p = 0.002).

Conclusions: Even if based on a small sample population, this proof-of-concept study poses the basis for an early identification of patients at higher risk of SARS-CoV-2 viremia, and therefore likely to develop severe COVID-19, and supports the need of a quantitative viral load determination in blood and respiratory samples of haematologic patients with COVID-19 in order to predict prognosis and consequently to help their further management.

Keywords: Viremia, SARS-CoV-2, COVID-19, ddPCR, Molecular diagnosis, Hematological malignancies

Background

Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) has been detected in specimens from multiple sites [1–3], including plasma. Its frequency ranges from 1 to 73% [2–11] in COVID-19 patients, and it seems to be significantly associated with adverse clinical outcomes [5, 7–10]. Preliminary data aside, the relationship between patients’ characteristics, plasma SARS-CoV-2 RNA, and the severity and outcome of COVID-19, remains largely unexplored.

In this study, we systematically quantified SARS-CoV-2 load in paired plasma and respiratory samples of 41 well characterized patients, with the aim of defining whether the presence of viremia could be correlated with clinical and/or laboratory characteristics, and COVID-19 outcome.

* Correspondence: claudia.alteri@unimi.it
2Department of Oncology and Hemato-oncology, Università degli Studi di Milano, Milan, Italy
Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Methods

Data collection

This proof-of-concept cross-sectional study included 41 SARS-CoV-2-positive adult patients hospitalized at Grande Ospedale Metropolitano Niguarda and at Fondazione IRCCS Policlinico Ca’ Granda (Milan, Italy) since March 01, 2020, and who have either died (N = 7) or been discharged (N = 34) by July 01, 2020, for those paired respiratory (nasopharyngeal swabs or bronchoalveolar lavages) and plasma samples were available. Demographic and clinical data were retrospectively collected thanks to pseudonymized electronic forms. The severity of the disease was classified in mild, moderate, severe and critical in line with WHO scale [12].

SOFA score and Charlson Comorbidity index were computed from the patients’ electronic medical records.

The study protocol was approved by the Ethical Committees of ASST Grande Ospedale Metropolitano Niguarda and IRCCS Ca’ Granda Ospedale Maggiore Policlinico Foundation (Prot. Numbers 92–15,032,020 and 0008489) and conducted in accordance with the principles of the 1964 Declaration of Helsinki. Study participation was by written informed consent. The requirement for informed consent was waived for ICU patients for those communication of information was impossible or characterized by disproportionate efforts [13].

SARS-CoV-2 quantification

Total RNA was extracted from 280 ul of respiratory samples or plasma samples using QIAamp viral RNA mini kit (Qiagen) following manufacturer’s instruction. SARS-CoV-2 genomic RNA was quantified by means of the QX200™ Droplet Digital™ PCR System (ddPCR, Biorad) using an home-made protocol targeting the RNA dependent RNA polymerase (RdRp) of SARS-CoV-2 and the housekeeping gene RNAse P [14, 15]. All results were further confirmed by using a second assay adapted for ddPCR and targeting two different portions of RdRp (https://www.who.int/docs/default-source/coronaviruse/real-time-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-pasteur-paris.pdf?sfvrsn=3662fcb6_2). SARS-CoV-2 quantification was finally expressed in number copies/mL.

Statistical analysis

Descriptive statistics are expressed as median values and interquartile range (IQR) for continuous data and number (percentage) for categorical data. To assess significant differences between patients with and patients without viremia, Fisher exact test and Wilcoxon test were used for categorical and continuous variables, respectively.

SPSS statistical software (version 23.0, IBM, Armonk, NY, USA) was used for statistical analysis.

Results

Patients’ characteristics

From March 01 through July 01, 2020, a total of 1801 patients received a diagnosis of SARS-CoV-2 infection at two of major hospital in Milan, Lombardy. Forty-one patients with available paired respiratory and plasma samples for SARS-CoV-2 detection were included in the analysis. Six of them (14.6%) were affected by haematological malignancies. Demographic, clinical, and laboratory, findings at admission, stratified by presence of SARS-CoV-2 in plasma, are reported in Table 1.

Thirteen patients (30.2%) were male, and median age was 59 (IQR: 50–67) years. Chest radiographs or CT scan confirmed a classical bilateral interstitial pneumonia in 95.1% of cases (39/41). Looking at the outcome available, 7 patients (17.1%) died in a median time of 28 (27–36) days from symptoms onset, and 34 (82.9%) were discharged in a median time of 54 (30–76) days from symptoms onset at the study endpoint.

SARS-CoV-2 load in respiratory and plasma samples

The presence of SARS-CoV-2 RNA in respiratory specimens was confirmed for all 41 patients, with a median (IQR) viral load of 3680 (595–166,800) copies/mL, with no difference between the bronchoalveolar lavages and nasopharyngeal swabs (median, IQR: 3180 [312–166,800] vs 9040 [671–6,800,000] copies/mL, p = 0.149). SARS-CoV-2 load was found in 8 plasma samples (19.5%), with a median (IQR) value of 694 (209–1023) copies/mL (Table 1).

Stratifying the population by plasma SARS-CoV-2 RNA, viremic patients were characterized by an higher mortality rate (50.0% vs 9.1%; p = 0.018) respect to no viremic patients. Respiratory failure was the leading cause of death in 3 out of 4 patients with SARS-CoV-2 viremia and in the 2 out 3 patients without evidence of SARS-CoV-2 in plasma. The underlying disease found in the remaining death with viremia was a T-cell lymphoma at advanced stage.

By looking at the characteristics of patients with viremia, we found that they were more frequently affected by haematological malignancies (5 [62.5%] vs. 1 [3.0%]; p < 0.001), and had higher viral load in respiratory samples (9,404,000 [586,060–10,000,000] vs 1560 [312–25,160] copies/mL; p = 0.002).

SARS-CoV-2 dynamics in the 8 patients with SARS-CoV-2 viremia

SARS-CoV-2 loads in plasma and respiratory samples of the 8 viremic patients in relation to day of symptoms onset was monitored until viremia clearance (defined as two consecutive negative plasma samples, Fig. 1), number of samples per patient median, [IQR]: 4 [2–6]). Viremia was detected since 12 (9–14) days after symptom onset, and viral clearance occurred while SARS-CoV-2 in
Table 1 Demographic, clinical, viral, and laboratory findings of 41 COVID-19 patients for those blood and respiratory specimens were available for SARS-CoV-2 detection

| Demographics and clinical characteristics | Overall, N = 41 | Sars-CoV-2 in the blood | P-value |
|------------------------------------------|----------------|-------------------------|---------|
|                                          |                | Present, N = 8 | Absent, N = 33 |
| Age, years                               | 59 (50–67)     | 65 (41–69) | 59 (50–66) | 0.469 |
| Sex                                      |                |            |            |       |
| Male                                     | 13 (30.2)      | 5 (62.5)   | 23 (69.7)  | 0.692 |
| Symptoms                                 |                |            |            |       |
| Fever                                    | 35 (85.4)      | 5 (62.5)   | 30 (90.9)  | 0.077 |
| Cough                                    | 24 (58.5)      | 3 (37.5)   | 21 (63.6)  | 0.172 |
| Dyspnea                                  | 28 (68.3)      | 5 (62.5)   | 23 (69.7)  | 0.692 |
| Evidence of interstitial pneumonia       | 39 (95.1)      | 7 (87.5)   | 32 (97.0)  | 0.356 |
| Chronic comorbidities                    | 27 (65.9)      | 6 (75.0)   | 21 (63.6)  | 0.435 |
| **Solid malignancy**                     | 5 (12.2)       | 1 (12.5)   | 4 (12.1)   | 0.683 |
| **Haematological malignancies**<sup>a</sup> | 6 (14.6)      | 5 (62.5)   | 1 (3.0)    | <0.001 |
| Diabetes                                 | 5 (12.2)       | 2 (25.0)   | 3 (9.1)    | 0.246 |
| Obesity                                  | 9 (22.0)       | 0 (0.0)    | 9 (23.7)   | 0.116 |
| Cardiovascular disease                   | 3 (7.3)        | 2 (25.0)   | 1 (3.0)    | 0.092 |
| Chronic obstructive lung disease         | 4 (9.8)        | 1 (12.5)   | 3 (9.1)    | 0.596 |
| Hypertension                             | 8 (19.5)       | 1 (12.5)   | 7 (21.2)   | 0.503 |
| Chronic kidney disease                   | 1 (2.4)        | 0 (0.0)    | 3 (9.1)    | 0.512 |
| Chronic liver disease                    | 1 (2.4)        | 0 (0.0)    | 1 (3.0)    | 0.805 |
| Other<sup>b</sup>                        | 3 (7.3)        | 0 (0.0)    | 3 (9.1)    | 0.512 |
| Immunosuppressive therapy                | 27 (65.8)      | 4 (50.0)   | 23 (69.9)  | 0.411 |
| SOFA score<sup>c</sup>                   | 3 (1–4)        | 2 (1–4)    | 3 (1–4)    |       |
| 0                                        | 5 (12.8)       | 0 (0.0)    | 5 (15.6)   | 0.828 |
| 1–2                                      | 12 (30.8)      | 4 (57.1)   | 8 (25.0)   |       |
| 3                                        | 8 (20.5)       | 1 (14.3)   | 7 (21.9)   |       |
| ≥ 4                                      | 14 (35.9)      | 2 (28.6)   | 12 (37.5)  |       |
| CHARLSON comorbidity index               | 2 (1–4)        | 4 (2–6)    | 2 (1–3)    |       |
| 0                                        | 7 (17.1)       | 1 (12.5)   | 6 (18.2)   | 0.298 |
| 1–2                                      | 19 (46.3)      | 2 (25.0)   | 17 (51.5)  |       |
| 3–4                                      | 8 (19.5)       | 2 (25.0)   | 6 (18.2)   |       |
| ≥ 5                                      | 7 (17.1)       | 3 (37.5)   | 4 (12.1)   |       |
| COVID-19 manifestation                   |                |            |            |       |
| **Critical**                             | 15 (36.6)      | 4 (50.0)   | 11 (33.3)  | 1.000 |
| **Severe**                               | 14 (34.1)      | 2 (25.0)   | 12 (36.4)  | 0.692 |
| **Moderate**                             | 11 (26.8)      | 2 (25.0)   | 9 (27.3)   | 1.000 |
| **Mild**                                 | 1 (2.4)        | 0 (0)      | 1 (3.0)    | 1.000 |
| Time from symptoms-onset to hospital admission, days | 5 (3–7) | 3 (1–5) | 6 (3–8) | 0.024 |

**SARS-CoV-2 load, ddPCR**

| Respiratory samples<sup>d</sup> | Viral load, copies/mL | 3680 (595–166,800) | 9,404,000 (586,060–10,000,000) | 1560 (312–25,160) | 0.002 |
| Blood samples                    | Viral load, copies/mL | 0 (0–0)          | 694 (209–1023) | 0 (0–0) | – |
respiratory samples was still detectable (SARS-CoV-2 load copies/mL median, [IQR]: 1,607,260 [1418-8,303,100]). Two patients died while still viremic.

Focus on hematological malignancies
As mentioned before, 5 out 6 patients affected by hematological malignancies were viremic for SARS-CoV-2 (Supplementary Table 1). Three of these 5 viremic patients were affected by large B-cell lymphoma (60.0%) and 4 received chemotherapy during COVID-19 (80.0%), with one patient receiving Bendamustine in combination with Gemcitabine and Vinorelbine (BEGEV). The median time to SARS-CoV-2 clearance in respiratory tract and plasma was of 6.5 (4.4–6.5) and 1.7 (1.5–3.0) weeks, respectively. The longer time for viral clearance in respiratory and peripheral tracts was observed in one patient

---

**Table 1** Demographic, clinical, viral, and laboratory findings of 41 COVID-19 patients for those blood and respiratory specimens were available for SARS-CoV-2 detection (Continued)

| Overall, N = 41 | Sars-CoV-2 in the blood | P-value |
|-----------------|-------------------------|---------|
|                 | Present, N = 8          | Absent, N = 33 |
| **Laboratory findings** |                         |         |
| White blood cell count, × 10⁹ per L | 8.43 (5.59–11.58) | 9 (2.70–9.90) | 8.30 (5.70–12.50) | 0.295 |
| Lymphocytes count, × 10⁹ per L | 0.74 (0.55–1.06) | 0.50 (0.40–1.00) | 0.80 (0.60–1.10) | 0.230 |
| Platelet count, × 10⁹ per L | 155 (78–274) | 108 (77–285) | 202 (78–274) | 0.567 |
| Total bilirubin, mg/mL | 0.47 (0.28–0.66) | 0.40 (0.20–0.80) | 0.50 (0.30–0.60) | 0.574 |
| Estimated glomerular filtration rate, mL/min | 83 (57–99) | 57 (46–105) | 88 (62–98) | 0.806 |
| Creatinine, μmol/L | 85 (70–107) | 107 (76–132) | 82 (69–98) | 0.264 |
| D-dimer, μg/mL | 1.08 (0.70–2.11) | 1.20 (0.80–3.20) | 1.10 (0.70–1.90) | 0.629 |
| IL-6, pg/mL | 53 (16–203) | 62 (28–134) | 44 (15–251) | 0.968 |
| Lactate dehydrogenase, U/L | 320 (220–422) | 236 (220–332) | 344 (217–552) | 0.252 |
| **Outcome** |                         |         |
| Death | 7 (17.1) | 4 (50.0) | 3 (9.1) | 0.018 |
| Time from symptoms-onset to death, days | 36 (27–83) | 31 (21–42) | 83 (28–98) | 0.400 |
| Discharged | 34 (82.9) | 4 (50.0) | 30 (90.9) | 0.018 |
| Time from symptoms-onset to discharge, days | 50 (33–73) | 38 (35–39) | 54 (30–77) | 0.621 |

Data are expressed as median (interquartile range), or N (%). P-values comparing COVID-19 patients with evidence of RNAemia to patients without RNAemia were calculated by Mann-Whitney U test, or Fisher’s exact test, as appropriate. P < 0.05 was considered statistical significant. ALT = alanine aminotransferase. AST = aspartate transaminase. COVID-19, coronavirus disease 2019. *Including: Large cell lymphoma (n = 4), T-cell lymphoma (n = 1), Hodgkin’s Lymphoma (n = 1).

*Including: Sarcoidosis (n = 1), Hashimoto’s thyroiditis (n = 1), renal transplantation (n = 1). *Information available for 39 individuals. †20 Bronchoalveolar lavages and 21 nasopharyngeal swabs. SARS-CoV-2 load did not differ between the two different samples (median, IQR: 3680, 366–166,800 vs 1530, 249–11,230, P = 0.419).

*Information available for 40 individuals

---

**Fig. 1** Decay of SARS-CoV-2 load in respiratory and blood samples of the 8 viremic patients, against time from symptoms onset. Box and whiskers plots indicates the distribution of SARS-CoV-2 load according to sample (respiratory vs. blood) and time from symptoms-onset. The upper and lower quartiles are represented by boxes, while the variability outside this range by whiskers. The median value is represented by a short line within the box.
affected by Hodgkin lymphoma and treated with BEGEV, followed by one patient affected by diffuse large B-cell lymphoma with a recent treatment history of high-dose methotrexate.

**Discussion**

In our study plasma SARS-CoV-2 RNA was found in 8 (19.5%) individuals, 6 (75.0%) of whom had a severe or critical COVID-19 manifestation and 4 (50.0%) died. This is in line with studies published so far, describing plasma SARS-CoV-2 RNA detectable in different percentage of COVID-19 patients, ranging from 0 to 73%, and frequently and significantly associated with worse clinical outcomes [2–11]. It should be noted that SARS-CoV-2 was not the first respiratory viral agent to be detected in blood of critical individuals. The viremic phase was frequently correlated with the severity of the disease and worse outcome in most viral infections, like those sustained by Rhinoviruses, Respiratory syncytial virus, Adenovirus, SARS-CoV, and Metapneumovirus [16–18].

Now that more evidence suggests a close relationship between viremia and severe COVID-19, the identification of specific factors or conditions that can define a population at risk of viremia is of utmost importance. In our study, plasma SARS-CoV-2 load was frequently detected in patients affected by hematological malignancies (62.5% vs. 3.0%, \( p < 0.001 \)), and with higher viral load in respiratory samples (9,404,000 [586,060-10,000, 000] vs. 1,560 [312–25,160] copies/mL, \( p = 0.002 \)), as compared to patients without viremia (Table 1). Previous studies on series of hospitalised patients showed that the concurrent haematological malignancies and COVID-19 are strongly related to mortality [19], and to prolonged viral shedding in the respiratory tract and serum samples [1, 20]. An episode of prolonged plasma SARS-CoV-2 RNA started prior to the onset of symptoms and diagnosis of COVID-19 was also recently described in a 51-year-old patient with acute myeloid leukemia, and thus with a heavily compromised immune status [21]. Consistent with these earlier reports, we found that viremia was detected since 12 (9–14) days from symptom onset, and viral undetectability in the blood occurred while SARS-CoV-2 in respiratory samples was still present. All these evidences may pose this fragile population at higher risk of developing a systemic infection, suggesting a potential utility of plasma SARS-CoV-2 RNA testing as a prognostic indicator in severe immunocompromised patients.

Our proof-of-concept study has some limitations. a) The small sample size and the high proportion of individuals with chronic comorbidities (80.5% of patients) prevented to appreciate a clear association between viremia and severe COVID-19, that preliminary data have already shown [7–10], as well as correlations between viremia and IL-6 or other knows COVID-19 prognostic markers (i.e. lymphocytes count, lactate dehydrogenase or D-dimer level) [5, 22, 23]. b) The correlation between viremia and the outcome was based only on 4 definitive events, requiring a confirmation on larger sample size. c) The real infectivity of the virus found in plasma was not assessed. Thus, it cannot be determined at present whether detectable RNA represents intact infectious virus or inactive, non-replicating nucleic acid. d) The study design, the heterogeneity of hematological malignancies and chemotherapies prevented to draw certain conclusions about correlations between these parameters and time to SARS-CoV-2 clearance. Even if the prolonged respiratory shedding and persistent viremia observed in one patient treated with the bendamustine is in line with recent findings, [24, 25] this observation requires further evaluation by ad hoc designed studies.

**Conclusion**

Our cross-sectional proof-of-concept study provides evidence for plasma SARS-CoV-2 load detection in the 19.5% of patients \( (n = 8) \), 50% of whom died, confirming the association between viremia and worse outcome [7–11]. Patients with SARS-CoV-2 in plasma were frequently characterized by haematological malignancies, and elevated viral load in respiratory samples. Although the associations here observed are based on a small population and need to be confirmed on a larger sample size, they pose the basis for an early identification of patients at higher risk of SARS-CoV-2 viremia, and therefore likely to develop severe COVID-19. This proof-of-concept study also supports the need of a quantitative viral load determination in blood and respiratory samples of haematologic patients with COVID-19 in order to predict prognosis and consequently to help their further management.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12879-021-05886-2.

**Additional file 1.**

**Abbreviations**

SARS-CoV-2: Severe Acute Respiratory Coronavirus 2; COVID-19: COronaVIrus Disease 2019; ARDS: Acute Respiratory Distress Syndrome; ddPCR: Droplet Digital PCR; RdRp: RNA dependent RNA polymerase

**Acknowledgements**

The authors also thank Dr. Valeria Castelli and Emanuele Palomba for outstanding technical support in data management.

**Authors’ contributions**

LC performed data collection, data analysis, data interpretation, writing; MA, SR, EM, CV, DF processed samples and collected data; SNM performed data processing; MM, GT, MV, JC, AM, GG, VS, EC, AB, AG, MP recruited samples and enrolled patients; CA conceived the study design and data
interpretation; CA, VC, AB, AG, and CFP, critically revised the manuscript. All authors have read and approved the manuscript.

Funding
This research was supported by the projects COMMUNITY (ID 1842163), funded by Regione Lombardia and co-funded under PCR FESR 2014–2020 resources. The founder had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Availability of data and materials
Data are described in Table 1, Supplementary Table 1 and Fig. 1. The datasets used in this study will be available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The study protocol was approved by the Ethical Committees of ASST Grande Ospedale Metropolitano Niguarda and IRCCS Ca’ Granda Ospedale Maggiore Policlinico Foundation (Prot. Numbers 92–15032020 and 0008489) and conducted in accordance with the principles of the 1964 Declaration of Helsinki. Study participation was by written informed consent. The requirement for informed consent was waived for ICU patients for those communication of information was impossible or characterized by disproportionate efforts (EDPB - Linee-guida 03/2020 sul trattamento dei dati relativi alla salute a fini di ricerca scientifica nel contesto dell’emergenza legata al COVID-19).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Laboratories, Unit of Diagnostic Microbiology and Immunology, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy.
2Department of Oncology and Hemato-oncology, Università degli Studi di Milano, Milan, Italy. *Infectious Diseases, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. †Centre for Multidisciplinary Research in Health Science, University of Milan, Milan, Italy. ‡Infectious Diseases Unit, IRCCS Ca’ Granda Ospedale Maggiore Policlinico Foundation, Milan, Italy.
3Department of Anesthesia and Critical Care, IRCCS Ca’ Granda Ospedale Maggiore Policlinico Foundation, Milan, Italy. ‡Chemical-clinical and Microbiological Analyses, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.

Received: 19 October 2020 Accepted: 9 February 2021

Published online: 17 February 2021

References
1. Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January–March 2020: retrospective cohort study. BMJ. 2020;369:m1443. https://doi.org/10.1136/bmj.m1443.
2. Peng L, Liu J, Xu W, et al. SARS-CoV-2 can be detected in urine, blood, anal swabs, and oropharyngeal swabs specimens. J Med Virol. 2020;92:1676-80. https://doi.org/10.1002/jmv.25936.
3. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323:1843-44. https://doi.org/10.1001/jama.2020.3786.
4. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019-nCoV in Wuhan City, China. Lancet. 2020;395:497-503. https://doi.org/10.1016/S0140-6736(20)30183-3.
5. Chen X, Qiao B, Qu Y, et al. Detectable serum SARS-CoV-2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clin Infect Dis. 2020;71:1937-42. https://doi.org/10.1093/cid/ciaa449.
6. Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020;9:386-9. https://doi.org/10.1080/22221751.2020.179071.
7. Chen W, Lan Y, Yuan X, et al. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. Emerg Microbes Infect. 2020;9:469-73. https://doi.org/10.1080/22221751.2020.1732837.
8. Hogan CA, Stevens B, et al. High frequency of SARS-CoV-2 RNAemia and association with severe disease. Clinical Infectious Dis. 2020;23:ciaa1054. https://doi.org/10.1093/cid/ciaa1054.
9. Hagman K, Hedenstierna M, Gille-Johnson P, et al. SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a retrospective cohort study. Clin Infect Dis. 2020;ciaa1285. https://doi.org/10.1093/cid/ciaa1285.
10. Eberhardt KA, Meyer-Schwickerath C, Heger E, et al. RNAemia Corresponds to Disease Severity and Antibody Response in Hospitalized COVID-19 Patients. Viruses. 2020;12:E1045. https://doi.org/10.3390/v12091045.
11. Veyer D, Kemés S, Pouget L, Wack M, Robillard N, Taly V, L'Honnère AS, Rozenberg F, Laurent-Puig P, Bélec L, Hadjadji J, Terrier B, Péret H. Highly sensitive quantification of plasma SARS-CoV-2 RNA sheds light on its potential clinical value. Clin Infect Dis. 2020;ciaa1196. https://doi.org/10.1093/cid/ciaa1196.
12. WHO. Clinical Management of COVID-19, Interim Guidance May. 2020. Available at https://apps.who.int/iris/rest/bitstreams/1278777/retrieve. Accessed 18 Oct 2020.
13. European Data Protection Board. Linee-guida 03/2020 sul trattamento dei dati relativi alla salute a fini di ricerca scientifica nel contesto dell’emergenza legata al COVID-19. EDPB. 2020. Available at EDPB - Linee-guida 03/2020 sul trattamento dei dati relativi alla salute. - Garante Privacy. Accessed 9 Jan 2021.
14. Alteri C, Cento V, Antonello M, et al. Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients. PLoS One. 2020;15:e0236311. https://doi.org/10.1371/journal.pone.0236311.
15. Research Use Only 2019-Novel Coronavirus (2019-nCoV) Real-time RT-PCR Primers and Probes. https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-patient-primer-probes.html. CDC. Updated June 6, 2020. Accessed 18 Oct 2020.
16. Campbell AP, Chien JW, Kuypers J, Englund JA, W ald A, Guthrie KA, Corey L, B昨k M. Respiratory virus pneumonia after hematopoietic cell transplantation (HCT): associations between viral load in bronchoalveolar lavage samples, viral RNA detection in serum samples, and clinical outcomes of HCT. J Infect Dis. 2020;201:1044-1013. https://doi.org/10.1086/651662.
17. Hung IF, Cheng VC, Wu AK, et al. Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis. 2004;10:1550-7. https://doi.org/10.3201/eid1009.040058.
18. Gu L, Qu J, Sun B, Yu X, Li H, Gao B. Sustained Viremia and high viral load in respiratory tract secretions are predictors for death in immunocompetent adults with adenovirus pneumonia. PLoS One. 2016;11:e0160776. https://doi.org/10.1371/journal.pone.0160776.
19. Martin-Moro F, Marquet J, Piriš M, et al. Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies. Br J Haematol. 2020;190:16-20. https://doi.org/10.1111/bjh.16801.
20. Karaatı A, İnyaka AÇ, Demiroğlu H, et al. Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma. Transfus Apher Sci. 2020;59:102871. https://doi.org/10.1016/j.transci.2020.102871.
21. Di Cristanziano V, Meyer-Schwickerath C, Eberhardt KA, et al. Detection of SARS-CoV-2 viremia before onset of COVID-19 symptoms in an allotransplanted patient with acute leukemia. Bone Marrow Transplant. 2020. https://doi.org/10.1038/s41409-020-01059-y.
22. Shi J, Li Y, Zhou X, et al. Lactate dehydrogenase and susceptibility to deterioration of mild COVID-19 patients: a multicenter nested case-control study. BMJ Med. 2020;18:168. https://doi.org/10.1186/s12986-020-01633-7.
23. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-62. https://doi.org/10.1016/S0140-6736(20)30566-3.
24. Lamure S, Duley R, Di Blasi R, et al. Determinants of outcome in Covid-19 hospitalized patients with lymphoma: a retrospective multicentric cohort study. E Clinical Medicine. 2020;27:100549. https://doi.org/10.1016/j.eclinm.2020.100549.
25. Nakajima Y, Ogai A, Furukawa K, et al. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. J Infect Chemother. 2020;27:387-9. https://doi.org/10.1016/j.jiac.2020.12.001.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.